|
🐜
|
Clinical significance of CD38 expression in chronic lymphocytic leukemia.
13 auth.
G. Poeta,
L. Maurillo,
A. Venditti,
F. Buccisano,
A. Epiceno,
Giovanni Capelli,
A. Tamburini,
G. Suppo,
Alessandra Battaglia,
M. I. Principe,
...
B. D. Moro,
M. Masi,
S. Amadori
|
8 |
2001 |
8
🐜
|
|
🐜
|
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia
16 auth.
F. Buccisano,
L. Maurillo,
V. Gattei,
G. Poeta,
M. I. Principe,
Maria Cristina Cox,
P. Panetta,
M. Consalvo,
Carla Mazzone,
B. Neri,
...
L. Ottaviani,
D. Fraboni,
A. Tamburini,
F. Lo‐Coco,
S. Amadori,
A. Venditti
|
6 |
2006 |
6
🐜
|
|
🐜
|
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation
14 auth.
A. Venditti,
L. Maurillo,
F. Buccisano,
G. Poeta,
Carla Mazzone,
A. Tamburini,
M. I. Principe,
M. Consalvo,
P. Fabritiis,
L. Cudillo,
...
Alessandra Picardi,
A. Franchi,
F. Coco,
S. Amadori
|
6 |
2003 |
6
🐜
|
|
🐜
|
Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy
8 auth.
P. Niscola,
M. I. Principe,
L. Maurillo,
A. Venditti,
F. Buccisano,
D. Piccioni,
...
S. Amadori,
G. Poeta
|
5 |
2005 |
5
🐜
|
|
🐜
|
Clinical significance of CD 38 expression in chronic lymphocytic leukemia
13 auth.
G. Poeta,
L. Maurillo,
A. Venditti,
F. Buccisano,
A. M. Epiceno,
G. Capelli,
A. Tamburini,
G. Suppo,
A. Battaglia,
M. I. Principe,
...
B. D. Moro,
M. Masi,
S. Amadori
|
5 |
2001 |
5
🐜
|
|
🐜
|
CD90/Thy‐1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias *
16 auth.
F. Buccisano,
F. Rossi,
A. Venditti,
G. Poeta,
M. Cox,
E. Abbruzzese,
M. Rupolo,
M. Berretta,
M. Degan,
S. Russo,
...
A. Tamburini,
L. Maurillo,
M. I. Principe,
M. Postorino,
S. Amadori,
V. Gattei
|
5 |
2004 |
5
🐜
|
|
🐜
|
NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment
18 auth.
M. D. Bo,
M. I. Principe,
F. Pozzo,
Dario Ragusa,
P. Bulian,
D. Rossi,
G. Capelli,
F. Rossi,
P. Niscola,
F. Buccisano,
...
R. Bomben,
A. Zucchetto,
L. Maurillo,
P. Fabritiis,
S. Amadori,
G. Gaidano,
V. Gattei,
G. Poeta
|
5 |
2014 |
5
🐜
|
|
🐜
|
Signature of B‐CLL with different prognosis by Shrunken centroids of surface antigen expression profiling
15 auth.
A. Zucchetto,
P. Sonego,
M. Degan,
R. Bomben,
M. D. Bo,
S. Russo,
V. Attadia,
M. Rupolo,
F. Buccisano,
M. I. Principe,
...
G. Poeta,
C. Pucillo,
A. Colombatti,
R. Campanini,
V. Gattei
|
5 |
2005 |
5
🐜
|
|
🐜
|
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients
19 auth.
F. Buccisano,
L. Maurillo,
A. Piciocchi,
M. I. Principe,
C. Sarlo,
Mariagiovanna Cefalo,
C. Ditto,
A. D. Veroli,
G. Santis,
M. Consalvo,
...
D. Fraboni,
P. Panetta,
P. Palomba,
Cristina Attrotto,
G. Poeta,
G. Sconocchia,
F. Lo‐Coco,
S. Amadori,
A. Venditti
|
5 |
2015 |
5
🐜
|
